Cartesian Therapeutics (RNAC) EBIAT: 2015-2025
Historic EBIAT for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -$35.9 million.
- Cartesian Therapeutics' EBIAT fell 48.46% to -$35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.0 million, marking a year-over-year increase of 80.40%. This contributed to the annual value of -$77.4 million for FY2024, which is 64.76% up from last year.
- According to the latest figures from Q3 2025, Cartesian Therapeutics' EBIAT is -$35.9 million, which was down 326.00% from $15.9 million recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' EBIAT ranged from a high of $28.8 million in Q1 2022 and a low of -$177.7 million during Q4 2023.
- Moreover, its 3-year median value for EBIAT was -$17.7 million (2025), whereas its average is -$30.4 million.
- As far as peak fluctuations go, Cartesian Therapeutics' EBIAT crashed by 3,114.73% in 2023, and later surged by 221.51% in 2024.
- Cartesian Therapeutics' EBIAT (Quarterly) stood at $12.2 million in 2021, then crashed by 51.85% to $5.9 million in 2022, then crashed by 3,114.73% to -$177.7 million in 2023, then spiked by 94.23% to -$10.3 million in 2024, then plummeted by 48.46% to -$35.9 million in 2025.
- Its EBIAT stands at -$35.9 million for Q3 2025, versus $15.9 million for Q2 2025 and -$17.7 million for Q1 2025.